A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 103.91%. However, over the past six months, we’ve seen a weaker performance of 74.00%. The price of RGLS fallen by 67.31% over the last 30 days. And in the last five days, it has surged by 76.35%.
Regulus Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $2.14 on 03/12/24, with the lowest value being $0.76 on 03/20/23.
52-week price history of RGLS Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Regulus Therapeutics Inc’s current trading price is 21.96% away from its 52-week high, while its distance from the 52-week low is 243.42%. The stock’s price range for this period has been between $0.76 and $2.14. The Healthcare sector company’s shares saw a trading volume of about 116.15 million for the day, which was higher than the average daily volume of 39420.0 over the last three months.
The Connection Between Financial Performance and Market Capitalization
Regulus Therapeutics Inc (RGLS) has experienced a quarterly rise of 86.43% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 52.77M and boasts a workforce of 30 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.3726, with a change in price of +2.0601. Similarly, Regulus Therapeutics Inc recorded 1,070,590 in trading volume during the last 100 days, posting a change of +159.70%.
RGLS’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for RGLS stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.04.
RGLS Stock Stochastic Average
As of today, the raw stochastic average of Regulus Therapeutics Inc over the last 50 days is at 83.77%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 82.19%. Further, the company’s Stochastic %K and %D values for the last 20 days were 36.53% and 26.65%, respectively.
